Survey

With the evolution of the medical home and ACO models of healthcare delivery, what do you see as the most essential means by which pharmacy departments can support the success of such models?

a) More active direct patient outreach, education, and consultation.

b) Enhanced provider education and drug info support.

c) Improved ability to deliver more timely and actionable patient-specific drug alerts to PCPs/care managers.

d) Enhanced mechanisms to monitor and improve patient compliance.

e) More advanced analytics to better risk stratify patients for intervention need.

f) More timely and robust reporting to measure pharmacy-specific quality performance metrics.

Digital Edition

FDA warns unapproved emergency birth control may be ineffective, unsafe

To confirm your e-newsletter subscription, click here.

To ensure future delivery of email newsletters from Formulary, please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff

FDA posts safety labeling changes
for 32 products

Statins may reduce risk of recurrent vascular events in young stroke patients

Young adults treated with a statin after a first ischemic stroke of undetermined cause were 77% less likely to suffer subsequent vascular events, according to a recent study published in Neurology. Read full article.

New guidelines for COPD diagnosis, management

The American College of Physicians (ACP), American College of Chest Physicians (ACCP), American Thoracic Society (ACT), and the European Respiratory Society (ERS) have issued updated recommendations to the 2007 ACP clinical practice guideline on diagnosis and management of stable chronic obstructive pulmonary disease (COPD). The new recommendations were published in Annals of Internal Medicine. Read full article.

FDA approves first antivenom
for Centruroides scorpion stings

FDA has approved the first antivenom treatment specifically for stings from Centruroides scorpions in the United States. The new biologic treatment called Anascorp was designated an orphan drug and given priority review because adequate treatment did not exist in the United States, according to a consumer update and corresponding news release issued by the agency. Read full article.

Results of biologics and specialty pharmacy research confirm knowledge gap

How much do employers know regarding biologics and specialty pharmacy? A recent survey indicates that while approximately half of employers had a moderate understanding related to biologics and specialty pharmacy, about one-third did not know how much their claim costs had increased over the last few years. Read full article.

FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer

FDA has approved vemurafenib (Zelboraf, Genentech), the second melanoma drug this year to improve overall survival. Zelboraf is indicated for the treatment of patients with late-stage (metastatic) or unresectable melanoma, the most dangerous type of skin cancer. Read full article.

FDA approves 2 new strengths of leuprolide acetate for treatment of children with central precocious puberty

FDA has approved 2 new strengths (11.25 mg and 30 mg) for 3-month administration of leuprolide acetate for depot suspension (Lupron Depot-PED, Abbott) for the treatment of children with central precocious puberty (CPP). Read full article.